1) Call to Order                              Charlene Fairfax, RPh

2) Minutes of Previous Meeting              Charlene Fairfax, RPh

3) Comments from Interested Parties*       Charlene Fairfax, RPh

4) Clinical Drug Class Reviews             Zakia Al-Amin, PharmD, BCACP, RPh
                                            Ronald E. Kavanagh, BSPharm, PharmD, PhD, RPh

- Androgenic Agents
- Antibiotics, Vaginal
- Antiemetics/Antivertigo Agents
- Antihyperuricemics
- Bladder Relaxants
- Bone Resorption and Suppression Agents
- BPH Agents
- Erythropoiesis Stimulating Agents
- GI Motility, Chronic, Irritable Syndrome
- Growth Hormone
- H. Pylori Agents
- Hepatitis C Agents
- Histamine-2-Receptor Antagonists

- Hypoglycemics, Incretin Mimetics/Enhancers
- Hypoglycemics, Insulins
- Hypoglycemics, Meglitinides
- Hypoglycemics, Metformins
- Hypoglycemics, SGLT2 Inhibitors
- Hypoglycemics, Thiazolidinediones
- Pancreatic Enzymes
- Phosphate Binders
- Progestins For Cachexia
- Proton Pump Inhibitors
- Ulcerative Colitis Agents
- Vaginal Estrogen Preparations

5) Executive Session (Committee Only)**     Charlene Fairfax, RPh
                                            MMA Representatives

6) Final Recommendations of Preferred Drugs*** MMA Representatives

7) Announcement of Next Scheduled P&T Committee Meeting Gidey Amare, RPh, MS
Thursday, June 2, 2016

8) Final Comments and Adjournment           Charlene Fairfax, RPh

*Individuals wishing to make oral presentations to the Committee will be limited to three (3) minutes only
**Closed Session  ***Open Session